Technology

DAVION HEALTHCARE ADOPTS DIRECT COMMERCIALISATION STRATEGY AND ESTABLISHES UK DISTRIBUTION PLATFORM

Published

3 months ago

June 22, 2026

DUBLIN, June 22, 2026 /PRNewswire/ — Davion Healthcare Plc (“Davion” or the “Company”), a next-generation digital healthcare company developing non-invasive, remote health monitoring solutions for the early detection of medical anomalies associated with serious health conditions, today announces an evolution of its commercial model designed to support the international rollout of its product portfolio and future acquisition strategy.

As previously announced, Davion continues to progress its proposed direct listing on the Nasdaq Global Market and remains engaged with the ongoing SEC review process. Management remains focused on executing the Company’s growth strategy and advancing its commercial initiatives.

Following a review of its commercial strategy, the Board has decided to move to a direct commercialisation model, enabling Davion and its subsidiaries to transact directly with regional distribution partners and customers in its target markets.

As part of this transition, the Company has exercised its contractual rights to terminate its existing global licensing and distribution arrangements relating to Davion BreastCheck.

The Board believes that direct commercialisation will provide Davion with greater control over product strategy, commercial execution and customer relationships, while establishing a scalable commercial platform capable of supporting both the Company’s existing product portfolio and future acquisitions.

To support this strategy, Davion further announces that it has entered into an agreement to acquire a controlling interest in Solar Medical and Chemical Limited (“Solar Medical”), a United Kingdom-based medical products distribution business.

Upon completion, Solar Medical is intended to become Davion’s principal commercial and distribution platform in the United Kingdom, supporting the rollout and market development of Davion BreastCheck, Davion FootFlow, Davion ThermaDerm and future products developed, acquired or commercialised by the Group.

The acquisition is intended to provide Davion with an owned UK operating capability and a scalable commercial infrastructure capable of supporting multiple products and serving as a platform for future acquisitions.

Outside the United Kingdom, Davion intends to appoint carefully selected regional distribution partners that will transact directly with Davion and its subsidiaries, including operating companies acquired or established by the Group from time to time.

The Board believes this model provides a scalable framework for international expansion and supports the continued development of Davion’s healthcare platform as the Company pursues its acquisition strategy. The revised commercial structure offers several strategic advantages, including:

Direct oversight of product deployment and commercial execution;An owned UK commercial and distribution capability;Greater control over customer relationships and market development;A scalable platform capable of supporting multiple products and future acquisitions; andA flexible framework for international expansion through carefully selected regional partnerships.

Jack Kaye, CEO of Davion Healthcare Plc, commented:

“This transition marks an important step in Davion’s evolution, as our objective is to move beyond individual licensing arrangements and establish a scalable commercial platform capable of supporting multiple products across our portfolio.

“The addition of Solar Medical is intended to provide Davion with an owned operating capability in the United Kingdom and a scalable platform from which to support future growth and international expansion through carefully selected regional partnerships.

“We believe this structure places Davion in a stronger position to support the rollout of Davion BreastCheck, Davion FootFlow, Davion ThermaDerm and future products as we continue to build a broader healthcare platform.”

The Company expects to provide further updates regarding completion of the Solar Medical transaction, product deployment plans and regional partnership arrangements in due course.

Contacts

Media Enquiries:
media@davionhealthcare.com

For more information please visit:
https://www.davionhealthcare.com/

FORWARD LOOKING STATEMENTS

This announcement contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, those identified by words such as “believes,” “will,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “targets,” “projects” and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company’s management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in these forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, the results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the impact of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, and other risks discussed from time to time in our filings with the Securities and Exchange Commission. We undertake no obligation to update any forward-looking statements, or any information contained in this press release or in other public disclosures, at any time. Finally, the investing public is reminded that only announcements or information about Davion Healthcare Plc disseminated by the Company and bearing its name are considered official.

View original content:https://www.prnewswire.com/news-releases/davion-healthcare-adopts-direct-commercialisation-strategy-and-establishes-uk-distribution-platform-302805511.html

SOURCE DAVION HEALTHCARE PLC

Technology

Function Now Connects to Meta’s Muse, Allowing Members to Bring Their Personal Health Data to the New AI Agent

Published

14 minutes ago

September 9, 2026

Members can securely bring their Function health data into Muse to better understand their health and personalize their AI experience.

AUSTIN, Texas, Sept. 8, 2026 /PRNewswire/ — Function today announced that members can securely connect their Function health data to Muse, Meta’s new personal AI agent. Muse joins ChatGPT, Claude, and Perplexity in Function’s growing network of AI connectors, giving members the ability to bring their personal health data into the AI experiences they choose to use.

Muse can use a member’s Function insights as personal context to help them understand their health, build and adapt plans around their goals, track progress, and follow through over time, while members remain in control of their data.

“Your AI should know your biology,” said Jonathan Swerdlin, CEO and Co-founder of Function. “By connecting Function health data to Muse, people can bring a living picture of their health into the AI platforms they use every day. We are entering a world where people understand their bodies in far greater detail and increasingly rely on AI to make decisions. Bringing those together makes AI dramatically more useful.”

How it works

Members authorize the connection from inside Meta, through the same account controls they already use to manage their account data. Once connected, Muse draws on their lab results and clinician-reviewed summaries to inform the goals and tasks a member brings to it.

Ask Muse how a lab result compares to a member’s optimal range before deciding whether to act on itHave Muse build or adjust a plan toward a health goal, using a member’s own Function insights as contextLet Muse flag when it’s time to schedule a member’s next Function lab visit, and follow up until it’s on the calendar

The Function health connector will roll out in the coming weeks. To learn more about Function or become a member, visit www.functionhealth.com.

About Function

Function is on a mission to enable everyone to live 100 healthy years. A groundbreaker in its category, Function has changed the game by making lab testing, MRI and CT, and longitudinal health data accessible, understandable, and actionable—serving millions. Function’s Medical Intelligence Lab™ (MI Lab™) is leveraging a dedicated clinical team to develop a continuous learning system that helps its members see, understand, and act on their biology over time. Members receive access to 160+ lab tests—including biannual testing—for just $365/year, equivalent to $1 per day, covering the heart, hormones, thyroid, liver, kidneys, heavy metal exposures, nutrient levels, inflammation, potential cancer signals, and more. Each member’s results are integrated into an intelligent, personalized interface designed to support powerfully informed decision-making. Function members can also access (for an additional cost) MRI and CT that are designed to see signs of cancer and hundreds of other conditions. Function believes everyone should have the power to own their health.

View original content to download multimedia:https://www.prnewswire.com/news-releases/function-now-connects-to-metas-muse-allowing-members-to-bring-their-personal-health-data-to-the-new-ai-agent-302872964.html

SOURCE Function Health

Technology

Teletrac Navman Appoints Ricardo Buranello as CEO

Published

14 minutes ago

September 9, 2026

Alain Samaha to Continue Serving on Board of Directors

SYDNEY, Sept. 9, 2026 /PRNewswire/ — Teletrac Navman, a leading global provider of intelligent fleet and asset management solutions, today announced that it has named current Chief Financial and Operating Officer Ricardo Buranello as Teletrac Navman’s next Chief Executive Officer, effective October 1, 2026. Mr Buranello succeeds Alain Samaha, who will continue in the CEO role through September 30, 2026, to ensure a seamless transition. Mr Samaha will remain a member of Teletrac Navman’s Board of Directors and continue supporting the Company’s long-term vision and strategic planning.

Mr Buranello is a seasoned executive with more than two decades of international experience across telematics, IoT, and high-growth technology businesses. Having served as Chief Financial and Operating Officer since joining Teletrac Navman, he brings deep financial and operational expertise, a strong strategic orientation, and an intimate knowledge of the business that make him ideally suited to lead the Company into its next chapter. Mr Buranello previously held leadership roles at Telit Cinterion, Siemens and Totvs.

“This represents an ideal time for Teletrac’s next phase of leadership, and we’re confident that Ricardo is the right person for the job,” said Jonathan Olefson, Chairman of the Board at Teletrac Navman. “Ricardo is a proven, mission-oriented leader who understands our business from the inside out. We look forward to what he and the entire team will accomplish.”

“Alain helped transform Teletrac into a global leader in telematics and fleet management solutions. We are grateful for his vision, passion, and many contributions, and look forward to working with him on the Board,” continued Olefson.

Mr Samaha stated, “Leading Teletrac has been one of the great privileges of my professional life. I am proud of what we have done together, and I am equally excited about what lies ahead for Teletrac. Ricardo is the right leader for this moment. His strategic clarity and deep understanding of our business will serve Teletrac, our customers, and our employees well into the future.”

Mr Buranello added, “I am honoured by the trust the Board has placed in me and energised by the opportunities ahead. Our customers, employees, and partners can count on the same dedication to innovation, excellence, and delivering meaningful results that has been at the core of Teletrac since the beginning.”

Under Mr Buranello’s leadership, Teletrac Navman will continue advancing its cloud-based, AI-powered connected mobility platform while building on the growth, stability, and customer focus that have long defined the Company.

About Teletrac Navman

Teletrac Navman empowers the industries that transform and sustain our futures with simple and intelligent solutions that enhance the efficiency, safety, and sustainability of their operation. As a connected mobility platform for industries that manage vehicle and equipment assets, Teletrac Navman simplifies the complex so that its customers can transform the way they work through cloud-based solutions that leverage AI to unlock the power of operational insight. The company operates globally, with offices worldwide and headquarters in Northbrook, IL. For more information visit https://www.teletracnavman.com.au/.

About Respida

Respida is a software-focused private equity firm with decades of combined investing and operating experience. The firm partners with management teams at growth-oriented software and software-enabled companies, bringing hands-on operational rigor and financial discipline to drive growth and build durable market leaders. For more information, visit https://respida.com/.

View original content:https://www.prnewswire.com/apac/news-releases/teletrac-navman-appoints-ricardo-buranello-as-ceo-302872980.html

SOURCE Teletrac Navman

Technology

Coda welcomes Bombay High Court judgment in its favor

Published

14 minutes ago

September 9, 2026

SINGAPORE, Sept. 8, 2026 /PRNewswire/ — Coda welcomed the Bombay High Court’s judgment on 2 September 2026 allowing the appeal by Coda Payments India and setting aside the orders that had kept its bank accounts and payment accounts frozen.

The judgment is a significant and positive outcome for Coda. We have been clear and consistent in our position throughout the proceedings and welcome the Court’s decision.

Coda has cooperated fully with the relevant authorities and respects the legal process. We now look forward to the judgment being implemented expeditiously and in full.

Coda remains committed to meeting all applicable legal and regulatory requirements in every market in which it operates.

The Bombay High Court’s judgment relates to the freeze on Coda Payments India’s bank accounts and payment accounts. Other related proceedings remain ongoing.

About Coda

Coda is a global leader in monetization, distribution, and commerce, trusted by the biggest names in gaming, entertainment, and technology, including Activision, Electronic Arts, Riot Games, Ubisoft, and Moonton. Founded in 2011 and headquartered in Singapore, Coda operates with 670+ employees worldwide, with core hubs in Asia and Europe. Coda combines payments, commerce, distribution, and rewards to drive global revenue growth for brands and publishers.

Coda’s products include Codapay, which provides access to 400+ payment methods across 80+ markets through a single API integration; Coda Webstore, which powers fully customized direct-to-consumer storefronts; Coda Consumer Platforms, including Codashop, Recharge.com, and Startselect.com; Coda Distribution, which extends reach through a network of commerce partners; and Giftcloud, a UK-based rewards business serving enterprise customers across Europe.

Coda is backed by Apis Partners, Insight Partners, Smash Capital, and GIC, and has been named an APAC High Growth Company (2023) by Financial Times, one of Granite Asia’s NextGenTech 30 (2024), a payments leader on Fortune’s Fintech Innovation Asia list (2024), and listed among The Straits Times Fastest Growing Fintechs (2024). For more on Coda, visit coda.co.

Press Contact
Coda:
Liz Adam
VP, Corporate Affairs
liz.adam@coda.co

View original content:https://www.prnewswire.com/apac/news-releases/coda-welcomes-bombay-high-court-judgment-in-its-favor-302872984.html

SOURCE Coda